Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function. Main question this study aims to answer is: Whether Dupilumab helps improve muscle activity of the esophagus in participants with EOE? Participants will: Take Dupilumab every week for 12 weeks. Visit the clinic before and after starting the medication. Keep a diary of symptoms.

NCT Number	NCT06665971
Lead Sponsor	University of California, San Diego Collaborators: Regeneron Pharmaceuticals
Conditions	Eosinophilic Esophagitis (EoE)
Enrollment	30 participants
Start Date	2024-11-10
Primary Completion	2026-09-15 (estimated)
Study Completion	2026-11-14 (estimated)
Updated on ClinicalTrials.gov	2024-12-11